Fig. 7.
Effect of srhCD40L on survival in MDA-231 tumor-bearing SCID mice. Mice were treated as described in Materials and Methods. Mice were treated 2 days after tumor cell injection. Treatment with srhCD40L or anti-CD40 resulted in significant (P < .01) increases in survival.